Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 7/20 | 0.47 |
| ▸ | TACR3 | P29371 | 7/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.47 |
| ▸ | CNR2 | P34972 | 5/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1173898 | 1.00 | TACR2 (0.47) | TACR2TACR3OPRM1CNR2GAA | |
| SCHEMBL1175231 | 0.91 | TACR2 (0.49) | TACR2TACR3OPRM1CNR2GAA | |
| SCHEMBL1175230 | 0.91 | TACR2 (0.49) | TACR2TACR3OPRM1CNR2GAA | |
| SCHEMBL1174348 | 0.90 | TACR2 (0.48) | TACR2TACR3OPRM1CNR2GAA | |
| SCHEMBL1174346 | 0.90 | TACR2 (0.48) | TACR2TACR3OPRM1CNR2GAA | |
| SCHEMBL1174831 | 0.86 | GAA (0.48) | TACR2TACR3OPRM1CNR2GAA | |
| SCHEMBL15234204 | 0.85 | CNR2 (0.48) | TACR2TACR3OPRM1CNR2GAA | |
| SCHEMBL15234397 | 0.85 | CNR2 (0.48) | TACR2TACR3OPRM1CNR2GAA | |
| SCHEMBL1174157 | 0.84 | CNR2 (0.49) | TACR2TACR3OPRM1CNR2GAA | |
| SCHEMBL1174159 | 0.84 | CNR2 (0.49) | TACR2TACR3OPRM1CNR2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859538-B2 | Uses of substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2014-10-14 | — | — | US | claimed |
| US-8859538-B2 | Uses of substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2170350-B1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS INC (US) | 2013-09-11 | — | — | EP | disclosed |
| US-8431565-B2 | Substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20110034443-A1 | USES OF SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-7517874-B2 | Substituted imidazo[1,5-a][1,4]diazepines and imidazo[1,5-a]pyrazines as cannabinoid receptor agonists for the treatment of pain | CARA THERAPEUTICS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20080318935-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CNR1, CNR2, TRPV1 | TACR2 157/4885TACR3 364/4885OPRM1 16/4885 |
| US-20110034443-A1 | USES OF SUBSTITUTED IMIDAZOHETEROCYCLES | CNR2, CNR1, TRPV1 | TACR2 192/4885TACR3 326/4885OPRM1 105/4885 |
| US-20080318935-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CNR1, CNR2, TRPV1 | TACR2 157/4885TACR3 364/4885OPRM1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.